2024-02-01 16:05:33 ET
In the three months ended December 31, 2023, the company reported a 2.6% increase in worldwide revenues, reaching $4.706 billion. However, there was a decline in respiratory illness-related sales compared to the previous year, and market dynamics in China negatively impacted the Medication Delivery Solutions unit. Operating expenses remained relatively flat, mainly due to lower shipping costs and cost containment measures, but there was an unfavorable impact from foreign currency translation. Th ... Full story available on KlickAnalytics.com